NYSE:ABBVBiotechs
What AbbVie (ABBV)'s Resilient 2025 Results and New Rinvoq Vitiligo Filings Mean For Shareholders
In early February 2026, AbbVie reported fourth-quarter 2025 sales of US$16,618 million and net income of US$1,816 million, alongside full-year 2025 sales of US$61.16 billion and net income of US$4.23 billion, and also filed for U.S. and European approval of Rinvoq for non-segmental vitiligo while preparing to present new immunology research at a Piper Sandler symposium.
The combination of growing revenues after Humira’s loss of exclusivity, ongoing label expansion for Rinvoq, and active R&D...